RecruitingPhase 2NCT06936943
ONO-4538 Study in Patients With Richter's Transformation
A Multicenter, Open-label, Uncontrolled Study to Evaluate the Efficacy and Safety of ONO-4538 in Patients With Richter's Transformation
Sponsor
Ono Pharmaceutical Co., Ltd.
Enrollment
14 participants
Start Date
Nov 19, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
Investigate the efficacy and safety of ONO-4538 in patients with Richter's transformation
Eligibility
Min Age: 18 Years
Inclusion Criteria5
- Histological diagnosis of diffuse large B-cell lymphoma (DLBCL)-type or Hodgkin lymphoma(HL)-type Richter's transformation with a history of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)
- In the case of DLBCL-type Richter's transformation, refractory, intolerant or ineligible for treatment of DLBCL
- Patients with measurable disease
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Expected to survive for 90 days or more
Exclusion Criteria4
- Serious complications
- Active multiple cancers
- Active central nervous system (CNS) disease
- History of allogeneic hematopoietic stem cell transplantation
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGONO-4538
every 4 weeks
Locations(10)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06936943